Targeting a specific tumor marker for imaging and treatment of mesothelioma
Targeting tumor-specific epitope for imaging and therapy for mesothelioma
This study is testing a new way to use targeted radiation therapy to treat the tough-to-treat sarcomatoid subtype of malignant mesothelioma, aiming to provide patients with a more effective and precise treatment that focuses on the tumor while protecting healthy tissue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11057986 on NIH RePORTER |
What this research studies
This research focuses on developing a new imaging and therapy approach for malignant mesothelioma, particularly the difficult-to-treat sarcomatoid subtype. It utilizes a targeted alpha therapy method that employs a specific antibody to deliver potent radiation directly to the tumor cells while minimizing damage to surrounding healthy tissues. The study aims to evaluate the effectiveness of a novel isotope pair for imaging and treatment, which has shown promise in preliminary tests. Patients may benefit from a more precise and effective treatment option tailored to their specific tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant mesothelioma, particularly those with the sarcomatoid subtype.
Not a fit: Patients with other types of cancer or those without mesothelioma may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with mesothelioma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown success with similar targeted therapies in different cancers, indicating potential for this novel approach in mesothelioma.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: He, Jiang — University of Virginia
- Study coordinator: He, Jiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.